Seres Therapeutics Financials - Benzinga

Seres Therapeutics Inc

MCRBNASDAQ

Trade with Public

Trade with Public

$4.91

-0.20-3.91%

At close: Aug 28, 5:00 PM EST

$4.91

-0.20-3.91%

Pre-Market: 7:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Seres Therapeutics Financials

Seres Therapeutics (MCRB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share

Benzinga Newsdesk

PRO
Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the analyst consensus estimate of $(1.88) by 10.64 percent. This is a 155.47 percent decrease over earnings of $3.75 per share

Benzinga Newsdesk

Earnings Scheduled For March 12, 2026

Benzinga Insights

PRO
Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.22) by 20.61 percent. This is a 10 percent decrease over losses of $(1.60) per share from

Benzinga Newsdesk

PRO
Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.67 by 40.3 percent. This is a 114.24 percent increase over losses of $(6.60) per share from

Benzinga Newsdesk

Earnings Scheduled For November 5, 2025

Benzinga Insights